Statements (21)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:clinical_trial
|
| gptkbp:conductedBy |
gptkb:World_Health_Organization
|
| gptkbp:enrolledCountries |
over 30
|
| gptkbp:enrolledPatients |
over 11,000
|
| gptkbp:focus |
gptkb:COVID-19
|
| https://www.w3.org/2000/01/rdf-schema#label |
Solidarity trial (WHO)
|
| gptkbp:publishedIn |
gptkb:New_England_Journal_of_Medicine
|
| gptkbp:purpose |
COVID-19 treatment research
|
| gptkbp:relatedTo |
gptkb:Solidarity_PLUS_trial
|
| gptkbp:result |
no significant reduction in mortality for tested drugs
|
| gptkbp:scope |
international
|
| gptkbp:startDate |
March 2020
|
| gptkbp:status |
completed
|
| gptkbp:studiedDrug |
gptkb:lopinavir/ritonavir
gptkb:remdesivir gptkb:interferon_beta-1a hydroxychloroquine |
| gptkbp:trial |
gptkb:clinical_trial
|
| gptkbp:website |
https://www.who.int/emergencies/diseases/novel-coronavirus-2019/global-research-on-novel-coronavirus-2019-ncov/solidarity-clinical-trial-for-covid-19-treatments
|
| gptkbp:bfsParent |
gptkb:remdesivir
|
| gptkbp:bfsLayer |
5
|